Companion Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Polymerase Chain Reaction Test ( PCR), Immunohistochemistry Test (IHC), In Situ Hybridization Test (ISH), Others), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Others), Regional Insights and Forecast to 2035

Companion Diagnostics Market Overview

Global Companion Diagnostics Market size is projected to reach USD 26051.77 Million by 2035, rising from USD 10091.18 Million in 2026 at a CAGR of 11.11%.

The Companion Diagnostics Market is expanding rapidly due to precision medicine adoption in oncology and molecular diagnostics. In 2025, global companion diagnostics usage reached 9.56 billion test applications across PCR, IHC, and ISH technologies . PCR-based assays accounted for 27.67 percent share, while oncology applications contributed 56.46 percent share of total diagnostic usage . More than 38 percent of pharmaceutical clinical trials integrate companion diagnostics. Over 62 percent of tests are performed on tissue samples globally. Regulatory approvals exceeded 45 CDx assays in 2025. Rising biomarker testing across 204 countries strengthens adoption. Increased use of targeted therapy drugs is driving diagnostic integration across hospitals and laboratories worldwide.

In the USA, the Companion Diagnostics Market dominates North America with 39.92 percent regional share in 2025 . The country performs over 4.2 million oncology-related companion diagnostic tests annually, mainly in lung and breast cancer. FDA-approved CDx assays exceed 25 active molecular tests. More than 68 percent of precision oncology prescriptions in the USA require diagnostic confirmation. Over 1,500 diagnostic laboratories support CDx workflows. PCR technology contributes 29 percent share of US diagnostic procedures. Leading pharmaceutical partnerships exceed 120 co-development programs. The USA leads biomarker research with over 3,800 active clinical trials integrating companion diagnostics.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising adoption of precision oncology drives 68 percent of total demand, supported by 56 percent oncology share and 27 percent PCR usage in diagnostics globally.
• Major Market Restraint: High testing costs affect 42 percent of healthcare facilities, while 31 percent of regions report limited reimbursement coverage impacting Companion Diagnostics Market adoption.
• Emerging Trends: NGS-based testing adoption increased by 18 percent, while liquid biopsy usage grew 22 percent, and AI-enabled diagnostics integration expanded by 25 percent in clinical labs.
• Regional Leadership: North America holds 39.92 percent share, followed by Europe at 27 percent, driven by strong clinical trial integration and 68 percent precision medicine adoption rate.
• Competitive Landscape: Top five companies control 40 percent market share, with Roche and Thermo Fisher leading 18 percent and 14 percent respectively in Companion Diagnostics Market.
• Market Segmentation: PCR leads with 27.67 percent share, IHC holds 21 percent, ISH contributes 12 percent, while oncology dominates with 56.46 percent application share globally.
• Recent Development: In 2025, over 45 FDA-approved CDx assays were introduced, with 12 new NGS-based tests launched and 18 percent growth in biomarker-linked drug approvals globally.

Latest Trends

The Companion Diagnostics Market is undergoing rapid transformation driven by precision oncology expansion, AI integration, liquid biopsy adoption, and next-generation sequencing (NGS) advancements. In 2025, oncology accounted for nearly 56.46% of total companion diagnostic utilization, while PCR-based technologies held around 27.67% share, reinforcing their dominance in clinical diagnostics. More than 38% of global oncology clinical trials now integrate companion diagnostics, reflecting strong alignment between drug development and biomarker testing. North America leads with approximately 39.92% market share, supported by over 120 pharmaceutical-diagnostic partnerships and widespread FDA-approved CDx assays. These structural shifts are accelerating innovation and reshaping diagnostic workflows across global healthcare systems.

One of the most significant trends is the rapid expansion of liquid biopsy-based companion diagnostics. Circulating tumor DNA (ctDNA) testing volumes increased by more than 30% in major oncology centers, enabling non-invasive cancer monitoring and therapy selection. Liquid biopsy reduces repeat tissue sampling procedures by nearly 29%, improving patient compliance and enabling real-time disease tracking. Multi-cancer early detection tests analyzing 50+ cancer types from a single blood sample are gaining commercial traction. This shift is especially strong in lung cancer and colorectal cancer monitoring programs, where over 60% of advanced cases are now evaluated using minimally invasive diagnostic approaches.

Market Dynamics

The Companion Diagnostics Market dynamics are shaped by precision medicine expansion, biomarker-driven therapies, and increasing integration of molecular testing into oncology treatment pathways. Over 56.46% of global demand is driven by oncology applications, while 27.67% is contributed by PCR-based testing technologies. More than 38% of clinical trials globally now include companion diagnostics for patient stratification, and over 4,000 active oncology studies are biomarker-linked. Rising adoption of next-generation sequencing, increasing regulatory approvals, and growing pharmaceutical-diagnostic collaborations exceeding 120 partnerships continue to strengthen market expansion across global healthcare systems.

Drivers

Rising adoption of precision oncology therapies

Rising adoption of precision oncology therapies is the primary driver of the Companion Diagnostics Market, contributing to nearly 68% of total demand across clinical applications. Over 56% of cancer treatments now require biomarker testing before drug administration, significantly increasing reliance on companion diagnostics. PCR and NGS technologies collectively account for more than 45% of diagnostic workflows in oncology settings. More than 3,800 clinical trials integrate companion diagnostics to ensure targeted therapy selection. Increasing cancer prevalence, affecting millions of patients annually, continues to drive demand for accurate molecular testing. Expanding pharmaceutical co-development programs, exceeding 120 global partnerships, further strengthen integration between drug development and diagnostic validation. Growing adoption of personalized medicine in hospitals and cancer research centers enhances survival outcomes by improving therapy matching accuracy by more than 35%, reinforcing long-term market expansion.

Restraints

High cost and reimbursement limitations

High cost of diagnostic technologies and limited reimbursement coverage are major restraints impacting 42% of healthcare institutions globally. Advanced platforms such as NGS-based testing are approximately 35% more expensive than conventional PCR methods, limiting adoption in cost-sensitive regions. Around 31% of healthcare systems lack standardized reimbursement frameworks for companion diagnostics, creating financial uncertainty for providers and patients. Regulatory complexity affects nearly 20% of diagnostic approvals, increasing development timelines and compliance costs. In addition, fragmented laboratory infrastructure limits accessibility in approximately 28% of developing healthcare regions. These factors collectively slow adoption of advanced companion diagnostics despite increasing demand for personalized therapies. Limited insurance coverage and high operational costs continue to restrict broader clinical integration across emerging and underdeveloped healthcare markets.

Opportunities

Expansion of liquid biopsy and NGS technologies

Expansion of liquid biopsy and next-generation sequencing technologies presents major opportunities in the Companion Diagnostics Market, with liquid biopsy adoption growing by 22% globally. Blood-based diagnostics reduce invasive procedures by nearly 40%, improving patient compliance and enabling continuous cancer monitoring. NGS platforms capable of analyzing over 500 genes per test are increasingly adopted in over 2,500 laboratories worldwide. More than 60% of lung cancer monitoring programs are transitioning toward non-invasive testing methods. Increasing pharmaceutical investment in biomarker development, supported by over 120 co-development agreements, enhances commercialization potential. Asia-Pacific contributes approximately 24% of global demand, offering strong growth opportunities due to expanding genomic infrastructure and rising cancer incidence. AI-enabled diagnostic systems improve accuracy by 25%, creating additional opportunities in automated pathology and predictive oncology analytics.

Challenges

Regulatory complexity and data interpretation issues

Regulatory complexity and genomic data interpretation challenges affect nearly 35% of multi-gene sequencing applications in the Companion Diagnostics Market. Approval processes for biomarker-linked diagnostics require extensive clinical validation, increasing development time by more than 20%. Around 28% of laboratories face infrastructure limitations for high-throughput sequencing and advanced molecular testing. Data standardization issues impact nearly 22% of global diagnostic consistency, especially in multi-regional clinical trials. Integration of genomic datasets exceeding 10,000 samples per analysis creates computational and interpretative complexity. Additionally, approximately 18% of healthcare institutions report shortages of skilled professionals trained in genomic diagnostics. These challenges slow adoption of advanced companion diagnostic technologies despite increasing demand for precision medicine and targeted therapies across oncology and rare disease applications.

Segmentation Analysis

The Companion Diagnostics Market is segmented based on technology type, clinical application, and end-use healthcare setting. Technology-based segmentation includes Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), and Next-Generation Sequencing (NGS), collectively accounting for over 100% utilization distribution across diagnostic workflows. PCR dominates with 27.67% share due to high sensitivity, while oncology applications contribute 56.46% of total demand globally. Hospital laboratories account for nearly 62% of testing volume, followed by reference laboratories at 28%. Increasing biomarker adoption across 3,800+ clinical trials supports segmentation expansion. Precision medicine integration across 204 countries further strengthens diagnostic stratification and personalized treatment selection worldwide.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

Polymerase Chain Reaction Test (PCR): PCR holds the largest share at 27.67% in the Companion Diagnostics Market due to its rapid amplification capability and high diagnostic accuracy exceeding 95% sensitivity in mutation detection. More than 4 million oncology-related PCR tests are conducted annually across global laboratories. It is widely used in detecting EGFR, KRAS, and BRAF mutations across lung and colorectal cancers. PCR adoption spans 68% of hospital-based diagnostic facilities. Its turnaround time is nearly 35% faster than conventional sequencing methods, making it the preferred first-line molecular diagnostic tool in precision oncology workflows.

Immunohistochemistry Test (IHC): IHC accounts for 21% share in the Companion Diagnostics Market and is widely used for protein expression analysis in tumor tissues. Over 62% of cancer diagnostic evaluations rely on tissue-based biomarker detection, where IHC plays a central role. It is extensively used in breast cancer diagnostics, contributing to 18% of IHC usage globally. More than 3,000 laboratories use IHC platforms for HER2, PD-L1, and hormone receptor testing. Diagnostic accuracy improvement reaches 20% when combined with molecular validation tools, strengthening its role in targeted therapy selection.

In Situ Hybridization Test (ISH): ISH contributes 12% share in the Companion Diagnostics Market, focusing on chromosomal and gene-level detection in oncology diagnostics. It is widely used for HER2 gene amplification testing, which accounts for nearly 25% of breast cancer diagnostic procedures. ISH is deployed in more than 1,800 diagnostic laboratories worldwide. It improves detection accuracy of gene abnormalities by nearly 30% compared to conventional staining methods. ISH is particularly important in solid tumor profiling and is increasingly integrated into multi-modal diagnostic workflows in precision oncology.

Others (NGS and Liquid Biopsy): Other technologies account for approximately 10% share in the Companion Diagnostics Market, primarily driven by Next-Generation Sequencing (NGS) and liquid biopsy platforms. NGS adoption has increased by 18% globally due to its ability to analyze over 500 genes in a single test. Liquid biopsy usage has grown by 22% in oncology monitoring, reducing invasive procedures by 40%. These technologies are used in more than 2,500 research institutions and support multi-gene profiling in over 40% of advanced cancer treatment programs.

By Application

Lung Cancer: Lung cancer represents 22% share in the Companion Diagnostics Market due to high global incidence exceeding 1.8 million annual cases requiring biomarker testing. EGFR mutation analysis is performed in over 60% of lung cancer patients before targeted therapy initiation. PCR and ISH are primary diagnostic tools in this segment. Companion diagnostics improve treatment response rates by approximately 40%, enabling personalized therapy selection. Increasing use of liquid biopsy in lung cancer monitoring has grown by 20%, supporting non-invasive disease tracking.

Breast Cancer: Breast cancer accounts for 18% share in the Companion Diagnostics Market with over 2.3 million new cases annually requiring HER2, ER, and PR biomarker testing. IHC is used in nearly 70% of breast cancer diagnostic procedures. Companion diagnostics improve therapy accuracy by 35%, significantly reducing ineffective treatment cycles. More than 15 FDA-approved assays support breast cancer CDx applications. Genomic profiling adoption has increased by 18%, strengthening precision treatment planning.

Colorectal Cancer: Colorectal cancer contributes 14% share in the Companion Diagnostics Market, driven by KRAS and NRAS mutation testing across 1.9 million global cases annually. Over 50% of patients undergo molecular profiling before therapy selection. PCR and NGS technologies dominate this segment. Diagnostic accuracy improves by nearly 30% with CDx integration. Targeted therapies supported by companion diagnostics enhance treatment efficiency by 25%, improving patient survival outcomes in clinical oncology settings.

Leukemia: Leukemia holds 10% share in the Companion Diagnostics Market, with approximately 475,000 annual cases requiring genetic mutation testing. PCR-based assays detect chromosomal abnormalities in nearly 80% of cases. More than 1,200 laboratories globally support leukemia diagnostic workflows. Companion diagnostics improve treatment response rates by 32% through precise molecular classification. Increasing adoption of genomic sequencing has enhanced early detection capabilities in hematological malignancies.

Melanoma: Melanoma represents 8% share in the Companion Diagnostics Market, driven by BRAF mutation testing in over 325,000 annual cases. NGS adoption in melanoma diagnostics has increased by 15%. Companion diagnostics improve targeted therapy outcomes by approximately 38%. More than 900 laboratories globally provide melanoma biomarker testing services. Early molecular detection significantly improves survival outcomes through personalized immunotherapy approaches.

Others: Other applications account for 28% share in the Companion Diagnostics Market, including prostate cancer and rare tumor diagnostics. Over 3 million diagnostic tests are performed annually in this category. NGS adoption has increased by 18%, enabling multi-gene analysis across rare disease cases. Diagnostic accuracy improves by 30% with biomarker-driven testing. More than 2,000 laboratories worldwide provide CDx services across diversified oncology applications.

Regional Outlook

The Companion Diagnostics Market demonstrates strong regional diversification driven by precision medicine adoption, cancer prevalence, healthcare infrastructure, and regulatory support. North America remains the leading regional market with approximately 39.92% share, supported by extensive biomarker testing programs and advanced molecular diagnostics capabilities. Europe accounts for nearly 28% of global demand due to widespread implementation of personalized medicine initiatives. Asia-Pacific represents about 23–24% of the market and is the fastest-expanding regional segment because of increasing genomic testing adoption and growing oncology patient populations. Middle East & Africa contributes approximately 8–9% share, supported by improving healthcare investments and expanding access to advanced diagnostic technologies.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the Companion Diagnostics Market with approximately 39.92% market share. The region benefits from advanced healthcare infrastructure, strong regulatory frameworks, and widespread adoption of precision medicine. The United States accounts for the majority of regional demand, supported by more than 120 FDA-approved companion diagnostic products and extensive utilization of biomarker-guided therapies. More than 80% of leading academic oncology centers across the region use next-generation sequencing panels for patient stratification and treatment selection. Clinical trial integration of companion diagnostics exceeds 70% in oncology-focused programs, strengthening market penetration. Favorable reimbursement policies and extensive pharmaceutical-diagnostic collaborations continue to support diagnostic adoption across hospitals and specialized laboratories. PCR technology remains the most commonly used platform, while liquid biopsy and AI-assisted molecular diagnostics are experiencing increasing utilization. Growing incidence of lung cancer, breast cancer, and colorectal cancer further drives testing volumes throughout North America. The region also hosts many of the world's leading diagnostic developers and biotechnology companies, creating a highly competitive innovation environment.

Europe

Europe represents approximately 28% of the global Companion Diagnostics Market and remains the second-largest regional market. Strong healthcare systems, increasing implementation of personalized medicine programs, and expanding molecular pathology infrastructure support market growth across the region. Germany, France, and the United Kingdom collectively account for more than 65% of regional companion diagnostic testing activity. More than 60% of oncology centers in Western Europe routinely perform genomic testing to support targeted treatment decisions. The implementation of In Vitro Diagnostic Regulation (IVDR) standards has accelerated laboratory modernization and validation processes across numerous healthcare institutions. Investments in laboratory automation increased by approximately 22% during recent years, improving testing efficiency and quality control. Companion diagnostics are increasingly integrated into national cancer management programs, supporting wider patient access to biomarker-based therapies. Molecular testing adoption continues to expand across breast cancer, lung cancer, colorectal cancer, and melanoma applications. Research funding dedicated to precision medicine initiatives accounts for approximately 40% of several major healthcare innovation programs in the region.

Asia-Pacific

Asia-Pacific accounts for approximately 23–24% of the Companion Diagnostics Market and is recognized as the fastest-growing regional segment. Rapid expansion of healthcare infrastructure, increasing cancer incidence, and growing investments in genomic medicine are key factors supporting regional development. China, Japan, India, South Korea, and Australia collectively contribute the majority of testing activity across the region. More than 1,000 research institutions are actively involved in precision medicine and molecular diagnostics initiatives. Adoption of next-generation sequencing technologies has increased significantly, supported by government-sponsored genomic programs and expanding reimbursement coverage. Large patient populations and rising awareness of targeted therapies have accelerated biomarker testing demand. Lung cancer remains a major application area due to high disease prevalence, while breast cancer and colorectal cancer testing continue to expand. Hospitals and diagnostic laboratories are investing in automation platforms, digital pathology systems, and AI-supported genomic analysis tools. Precision oncology programs are being integrated into national healthcare strategies across several countries. Increasing pharmaceutical partnerships and clinical research activities further strengthen the regional ecosystem.

Middle East & Africa

Middle East & Africa accounts for approximately 8–9% of the Companion Diagnostics Market. Although comparatively smaller in market size, the region is witnessing steady expansion due to increasing healthcare investments and gradual adoption of precision medicine practices. Countries including the United Arab Emirates, Saudi Arabia, and South Africa are leading regional implementation of molecular diagnostic technologies. Oncology remains the primary application area, accounting for more than 50% of companion diagnostic utilization within the region. Healthcare modernization programs are supporting the establishment of advanced diagnostic laboratories and genomic testing centers. Government initiatives focused on cancer screening and early disease detection are increasing awareness of biomarker-based diagnostics. International collaborations with pharmaceutical and biotechnology companies are facilitating technology transfer and laboratory capability enhancement. Adoption of PCR-based companion diagnostic testing remains dominant due to cost efficiency and established clinical utility. Increasing availability of NGS platforms is expanding opportunities for comprehensive genomic profiling in specialized medical centers.

List of Top Companion Diagnostics Market Companies

• Roche Diagnostics
• Abbott Laboratories
• Agilent Technologies
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Myriad Genetics Inc.
• Covance
• Illumina
• Siemens Healthineers
• Takeda
• Tocagen

Top 2 Companies Market Share

• Roche Diagnostics – 18 percent global Companion Diagnostics Market share driven by strong oncology CDx portfolio and FDA-approved assays
• Thermo Fisher Scientific – 14 percent global share supported by PCR-based diagnostic systems and 120+ pharmaceutical collaborations

Investment Analysis and Opportunities

Investment activity in the Companion Diagnostics Market continues to accelerate as pharmaceutical companies, biotechnology firms, and diagnostic developers increase funding for precision medicine programs. More than 38% of global oncology clinical trials now incorporate companion diagnostics for biomarker identification and patient stratification. The growing requirement for targeted therapies has resulted in over 120 active co-development partnerships between drug manufacturers and diagnostic companies, creating substantial investment opportunities across molecular testing platforms and biomarker discovery programs.

Next-generation sequencing (NGS) remains a primary investment focus, with adoption rates increasing by approximately 18% across oncology testing laboratories. More than 500 actionable genomic biomarkers are currently being evaluated through advanced sequencing platforms, encouraging investment in high-throughput diagnostic technologies. Companies are expanding laboratory capacity, automation systems, and genomic data analysis infrastructure to support growing testing volumes and precision medicine initiatives.

Liquid biopsy represents one of the most attractive opportunity areas within the Companion Diagnostics Market. Blood-based testing utilization increased by 22% during recent years due to its ability to provide non-invasive cancer monitoring and treatment selection. Clinical studies indicate that liquid biopsy technologies can reduce invasive tissue collection procedures by nearly 40%, making them increasingly attractive for healthcare providers and investors.

New Product Development

Product innovation within the Companion Diagnostics Market accelerated significantly during 2024 and 2025, driven by advances in next-generation sequencing (NGS), liquid biopsy technologies, artificial intelligence, and biomarker-guided oncology therapies. More than 40 newly approved or expanded companion diagnostic indications were added across major regulatory markets, reflecting increasing integration between diagnostic developers and pharmaceutical manufacturers. FDA-approved companion diagnostic platforms now support testing for over 30 actionable genomic biomarkers linked to targeted therapies.

A major development was the expansion of comprehensive genomic profiling solutions. In August 2024, Illumina received FDA approval for TruSight Oncology Comprehensive, a diagnostic platform analyzing more than 500 genes from solid tumors. The test introduced companion diagnostic claims for NTRK fusion-positive cancers and additional biomarker-guided therapies, allowing broader genomic assessment from a single tissue sample. The platform significantly expanded precision oncology testing capabilities across hospitals and cancer centers.

Liquid biopsy innovation also accelerated. In 2024, FoundationOne Liquid CDx gained additional FDA approval for identifying BRCA-positive metastatic castration-resistant prostate cancer patients eligible for targeted treatment. The assay utilizes plasma samples instead of tissue biopsies, improving patient accessibility and reducing invasive procedures.

Five Recent Developments (2023-2025)

• 2025: FDA approved over 25 new companion diagnostic assays for oncology applications globally
• 2024: Thermo Fisher expanded PCR-based CDx portfolio with 18 percent increase in test sensitivity
• 2024: Roche launched 5 new IHC-based biomarker assays for breast and gastric cancer
• 2023: Illumina introduced NGS-based oncology platform supporting 20 percent faster genomic analysis
• 2023: Over 120 pharmaceutical-CDx co-development programs initiated worldwide

Report Coverage

The Companion Diagnostics Market report provides comprehensive analysis of companion diagnostic technologies, biomarker-based testing platforms, clinical applications, competitive positioning, and regional performance across major healthcare economies. The study evaluates key technologies including Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), and other molecular diagnostic platforms used in precision medicine programs. PCR remained the leading technology segment with a 27.67% market share in 2025, while tissue-based testing accounted for 62.58% of total diagnostic utilization globally.

The report examines application-specific demand across lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, and other oncology indications. Oncology continues to represent the largest application area, supported by increasing adoption of targeted therapies and biomarker-guided treatment pathways. The analysis includes evaluation of more than 4,000 active precision medicine and biomarker-driven clinical studies worldwide, highlighting the growing role of companion diagnostics in therapy selection and patient stratification.

Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, with detailed assessment of healthcare infrastructure, regulatory frameworks, testing adoption, and innovation activity. North America accounted for 39.92% of global market share in 2025, supported by advanced molecular testing capabilities, strong pharmaceutical collaborations, and widespread precision oncology implementation.

Companion Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 10091.18 Billion in 2026
Market Size Value By	USD 26051.77 Billion by 2035
Growth Rate	CAGR of 11.11% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Polymerase Chain Reaction Test ( PCR) Immunohistochemistry Test (IHC) In Situ Hybridization Test (ISH) Others By Application : Lung Cancer Breast Cancer Colorectal Cancer Leukemia Melanoma Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample